

Marion Vermeulen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9280333/marion-vermeulen-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

48
papers

1,848
citations

19
h-index

42
g-index

55
ext. papers

2,408
ext. citations

5.4
avg, IF

5.01
L-index

#	Paper	IF	Citations
48	Convalescent plasma in the treatment of moderate to severe COVID-19 pneumonia: a randomized controlled trial (PROTECT-Patient Trial).. <i>Scientific Reports</i> , 2022 , 12, 2552	4.9	4
47	Estimates of prevalence of anti-SARS-CoV-2 antibodies among blood donors in eight provinces of South Africa in November 2021. 2022 ,		1
46	Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape, KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021 2021 ,		21
45	Rapid and Successful Implementation of a COVID-19 Convalescent Plasma Programme-The South African Experience. <i>Viruses</i> , 2021 , 13,	6.2	1
44	Transfusion medicine and blood banking education and training for blood establishment laboratory staff: A review of selected countries in Africa. <i>Transfusion</i> , 2021 , 61, 1955-1965	2.9	2
43	SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. <i>Nature Medicine</i> , 2021 , 27, 622-625	50.5	670
42	Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. <i>Vox Sanguinis</i> , 2021 , 116, 872-879	3.1	1
41	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Protocols, Challenges and Lessons Learned: Summary. <i>Vox Sanguinis</i> , 2021 , 116, 1117-1135	3.1	0
40	International Forum on the Collection and Use of COVID-19 Convalescent Plasma: Responses. <i>Vox Sanguinis</i> , 2021 , 116, e71-e120	3.1	1
39	An assessment of hepatitis B virus prevalence in South African young blood donors born after the implementation of the infant hepatitis B virus immunization program: Implications for transfusion safety. <i>Transfusion</i> , 2021 , 61, 2688-2700	2.9	2
38	Undisclosed HIV status and antiretroviral therapy use among South African blood donors. <i>Transfusion</i> , 2021 , 61, 2392-2400	2.9	2
37	Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries. <i>Vox Sanguinis</i> , 2021 , 116, 18-35	3.1	27
36	HIV incidence in South African blood donors from 2012 to 2016: a comparison of estimation methods. <i>Vox Sanguinis</i> , 2021 , 116, 71-80	3.1	4
35	ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group. <i>Vox Sanguinis</i> , 2021 , 116, 849-861	3.1	41
34	Modeling global transfusion medicine education. <i>Transfusion</i> , 2021 , 61, 3040-3049	2.9	1
33	Direct comparison of three residual risk models for hepatitis B virus window period infections using updated input parameters. <i>Vox Sanguinis</i> , 2020 , 115, 133-145	3.1	9
32	Comparison of two nucleic acid amplification technology systems for detection of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus. <i>Transfusion</i> , 2020 , 60, 2929-2937	2.9	1

31	Health economic implications of testing blood donors in South Africa for HTLV 1 & 2 infection. <i>Vox Sanguinis</i> , 2019 , 114, 467-477	3.1	3
30	International Forum on Occult hepatitis B infection and transfusion safety. <i>Vox Sanguinis</i> , 2019 , 114, e1-e35	3.1	2
29	The prevalence of human T-lymphotropic virus type 1 & 2 (HTLV-1/2) in South African blood donors. <i>Vox Sanguinis</i> , 2019 , 114, 451-458	3.1	12
28	Discovery of False Elite Controllers: HIV Antibody-Positive RNA-Negative Blood Donors Found To Be on Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2019 , 220, 643-647	7	15
27	Reassessment of hepatitis B virus window periods for two transcription-mediated amplification assays using screening data of South African blood donors. <i>Transfusion</i> , 2019 , 59, 2922-2930	2.9	6
26	Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes. <i>Transfusion</i> , 2019 , 59, 267-276	2.9	25
25	Substantial variation in the hepatitis B surface antigen (HBsAg) in hepatitis B virus (HBV)-positive patients from South Africa: Reliable detection of HBV by the Elecsys HBsAg II assay. <i>Journal of Clinical Virology</i> , 2018 , 101, 38-43	14.5	10
24	A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios. <i>Transfusion</i> , 2017 , 57, 841-849	2.9	26
23	Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa. <i>Emerging Infectious Diseases</i> , 2017 , 23, 1560-1563	10.2	8
22	Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing. <i>Transfusion</i> , 2017 , 57, 24-35	2.9	39
21	Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. <i>PLoS Pathogens</i> , 2016 , 12, e1005742	7.6	61
20	The current status of nucleic acid amplification technology in transfusion-transmitted infectious disease testing. <i>ISBT Science Series</i> , 2016 , 11, 123-128	1.1	4
19	The use of rapid diagnostic tests for transfusion infectious screening in Africa: a literature review. <i>Transfusion Medicine Reviews</i> , 2015 , 29, 35-44	7.4	38
18	Response to article entitled, Health policy implications of blood transfusion-related human T-cell lymphotropic virus type 1 infection and disease. <i>Southern African Journal of Infectious Diseases</i> , 2015 , 30, 147-147	0.4	
17	A mathematical approach to estimate the efficacy of individual-donation and minipool nucleic acid amplification test options in preventing transmission risk by window period and occult hepatitis B virus infections. <i>Transfusion</i> , 2014 , 54, 2496-504	2.9	19
16	Sensitivity of individual-donation and minipool nucleic acid amplification test options in detecting window period and occult hepatitis B virus infections. <i>Transfusion</i> , 2013 , 53, 2459-66	2.9	46
15	Comparison of viral Env proteins from acute and chronic infections with subtype C human immunodeficiency virus type 1 identifies differences in glycosylation and CCR5 utilization and suggests a new strategy for immunogen design. <i>Journal of Virology</i> , 2013 , 87, 7218-33	6.6	93
14	Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk. <i>Transfusion</i> , 2013 , 53, 2384-98	2.9	27

13	Comment on: One window-period donation in two years of individual donor-nucleic acid test screening for hepatitis B, hepatitis C and human immunodeficiency virus. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2013 , 35, 225-6		
12	Hepatitis B virus transmission by blood transfusion during 4 years of individual-donation nucleic acid testing in South Africa: estimated and observed window period risk. <i>Transfusion</i> , 2012 , 52, 880-92	2.9	58
11	Blood transfusion safety in Africa: a literature review of infectious disease and organizational challenges. <i>Transfusion Medicine Reviews</i> , 2012 , 26, 164-80	7.4	106
10	High seroprevalence of enterovirus infections in apes and old world monkeys. <i>Emerging Infectious Diseases</i> , 2012 , 18, 283-6	10.2	17
9	Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin $\alpha\alpha$. <i>PLoS Pathogens</i> , 2012 , 8, e1002686	7.6	120
8	Pilot studies for development of an HIV subtype panel for surveillance of global diversity. <i>AIDS Research and Human Retroviruses</i> , 2012 , 28, 594-606	1.6	13
7	Seroconverting blood donors as a resource for characterising and optimising recent infection testing algorithms for incidence estimation. <i>PLoS ONE</i> , 2011 , 6, e20027	3.7	7
6	Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms. <i>Transfusion</i> , 2011 , 51, 203-15	2.9	82
5	Changing epidemiology of human parvovirus 4 infection in sub-Saharan Africa. <i>Emerging Infectious Diseases</i> , 2010 , 16, 1605-7	10.2	49
4	Characterization of occult hepatitis B virus strains in South African blood donors. <i>Hepatology</i> , 2009 , 49, 1868-76	11.2	62
3	Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa. <i>Transfusion</i> , 2009 , 49, 1115-25	2.9	103
2	Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021		4
1	Prevalence of anti-SARS-CoV-2 antibodies among blood donors in South Africa during the period January-May 2021		2